HSPG2 and neoplasm: In addition to the development of new antagonistic molecules, pharmacological research for the inhibition of Wnt/β-catenin signaling in PLC could be directed towards the repurposing of non-oncology drugs, already active for other diseases, and the evaluation of natural compounds that may have an anti-inflammatory effect on the tumor microenvironment [130] (see Table 2).